1993
DOI: 10.1055/s-2007-1013891 View full text |Buy / Rent full text
|
|

Abstract: We studied the effects of four different doses of recombinant human erythropoietin (rhEPO) on the amount of preoperative autologous blood donation. 43 patients prior to open heart surgery were randomized into 5 groups (100, 200, 400, 800 U/kg rhEPO i.v. or placebo) and treated twice weekly over a period of 4 weeks. Autologous blood was taken at a hemoglobin of 13 g/dl and a hematocrit of 34% respectively. Application of low-dose rhEPO (100 and 200 U/kg) did not increase the amount of autologous blood donated, … Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
0
11
0
1

Year Published

1996
1996
2012
2012

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

0
11
0
1
Order By: Relevance
“…The use of erythropoietin in cardiac surgery has been studied in 12 RCTs and has been shown to be associated with significant risk reduction in allogeneic blood transfusion after cardiac surgery. [1112][1113][1114][1115][1116][1117][1118][1119][1120][1121][1122] However, the data from the RCTs are heterogeneous, with different doses of erythropoietin administered for 1 to 3 weeks preoperatively; as a result, further studies are needed to define more precisely the patient subgroups who may benefit from this therapy. 1123 In patients who refuse blood transfusions during cardiac surgery, a short-term course of preoperative erythropoietin, to produce a high hematocrit preoperatively, may be administered.…”
Section: Hillis Et Al 2011 Accf/aha Cabg Guideline E693mentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 100,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…The use of erythropoietin in cardiac surgery has been studied in 12 RCTs and has been shown to be associated with significant risk reduction in allogeneic blood transfusion after cardiac surgery. [1112][1113][1114][1115][1116][1117][1118][1119][1120][1121][1122] However, the data from the RCTs are heterogeneous, with different doses of erythropoietin administered for 1 to 3 weeks preoperatively; as a result, further studies are needed to define more precisely the patient subgroups who may benefit from this therapy. 1123 In patients who refuse blood transfusions during cardiac surgery, a short-term course of preoperative erythropoietin, to produce a high hematocrit preoperatively, may be administered.…”
Section: Hillis Et Al 2011 Accf/aha Cabg Guideline E693mentioning
“…Recombinant human erythropoietin is used in combination with iron supplementation to treat anemic patients (hemoglobin levels Ͻ13 g/dL) with renal failure and those undergoing chemotherapy. The use of erythropoietin in cardiac surgery has been studied in 12 RCTs and has been shown to be associated with significant risk reduction in allogeneic blood transfusion after cardiac surgery (1112)(1113)(1114)(1115)(1116)(1117)(1118)(1119)(1120)(1121)(1122). However, the data from the RCTs are heterogeneous, with different doses of erythropoietin administered for 1 to 3 weeks preoperatively; as a result, further studies are needed to define more precisely the patient subgroups who may benefit from this therapy (1123).…”
Section: Perioperative Bleeding/transfusion: Recommendationsmentioning
“…The current storage and preservation techniques allow us to collect and maintain 2 to 4 units of full blood or PRBCs. This efficacy can be enhanced by stimulation of erythropoiesis during blood donation, but this is used only selectively because of the potential of thrombotic cardiovascular events and costs [11,12]. The use of erythropoietin is also limited by the necessity of starting its administration 3 weeks before surgery [13].…”
Section: Pre-operative Autologous Blood Donationmentioning